This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RELB · Western blot design guide
RELB Western Blot Planning Guide
Plan a RELB Western blot around the catalog-observed 62.1 kDa band, image-backed PA1803 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
RELB Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 62.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Skin | |
| Negative control | Skeletal muscle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 62.1 kDa |
| ⓘ | Localization | Nucleus / Cytoplasm, cytoskeleton, microtubule organizing center, centrosome |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated RELB Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Breast |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PA1803 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected RELB Western Blot Band Size?
Use the product-observed 62.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 62.1 kDa | Matches the authoritative product WB observation. |
| 62.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected RELB appearancePlan around 62.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 62.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 62.1 kDa from UniProt Q01201; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PA1803. |
| Situation | Likely cause | Next action |
|---|---|---|
| 62.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing RELB band
PA1803 · RELB
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for RELB Western blot
🧪Use Skin as the first positive-control candidate and Skeletal muscle as the HPA Not detected negative candidate.
Positive control: Skin (High)
Negative control: Skeletal muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for RELB
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Section 3
Advanced RELB Western Blot Tips
Deeper troubleshooting and optimisation questions for RELB, answered from its protein features.
Which band should guide the blot?
Use 62.1 kDa, the observation attached to the authoritative PA1803 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 62.1 kDa expectation.
Which positive control should I start with?
Start with Skin, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Skeletal muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for RELB Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA1803 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
RELB Western Blot Reagents
Human/Mouse/Rat-reactive RELB Western blot reagents with authoritative product imagery.
Real WB data
Anti-Rel B/RELB Antibody Picoband®
Cat # PA1803
Real WB data
Anti-Rel B/RELB Antibody Picoband®
Cat # PB9799
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q01201
- Human Protein Atlas — RELB
- PA1803 product record
- PMC2912378 — Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production (PloS one, 2010)
- PMC2900382 — Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation (Journal of cellular physiology, 2009)
